HpVac

Switzerland
Hasle, Lucerne, Switzerland, Switzerland

Company profile

HpVac company profile

GBC-HpVac focuses on the development of GBC-R1 as a preventive and therapeutic first-line therapy for asthma and related allergic diseases. GBC-HpVac holds an exclusive, worldwide license from the University of Zurich. GBC-HpVac was founded in 2016 and is headquartered in Geneva, Switzerland.

Business identity

Contact email
[email protected]
Phone number
+41 22 794 40 20
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2016-06-01

Headquarters

Postal code
Switzerland
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
3
Total equity funding
$2.4M
Last funding
Seed / $1M / 2021-02-01
Last equity funding
Seed / $1M
Articles
3

Founders and investors

No public relation records are available.